0001179110-19-003505.txt : 20190307
0001179110-19-003505.hdr.sgml : 20190307
20190307151902
ACCESSION NUMBER: 0001179110-19-003505
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190307
FILED AS OF DATE: 20190307
DATE AS OF CHANGE: 20190307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SAUNDERS BRENT L
CENTRAL INDEX KEY: 0001268854
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36867
FILM NUMBER: 19665659
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
STREET 2: C/O SCHERING PLOUGH CORP
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allergan plc
CENTRAL INDEX KEY: 0001578845
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
BUSINESS PHONE: (216) 523-5000
MAIL ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis plc
DATE OF NAME CHANGE: 20130930
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis Ltd
DATE OF NAME CHANGE: 20130607
4
1
edgar.xml
FORM 4 -
X0306
4
2019-03-07
0
0001578845
Allergan plc
AGN
0001268854
SAUNDERS BRENT L
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,
COOLOCK, CO.
DUBLIN
L2
D17 E400
IRELAND
1
1
0
0
Chairman, President and CEO
Ordinary Shares, par value $0.0001
2019-03-07
4
P
0
300
142.18
A
169206.29
D
Ordinary Shares, par value $0.0001
2019-03-07
4
P
0
860
143.70
A
170066.29
D
Ordinary Shares, par value $0.0001
2019-03-07
4
P
0
600
144.37
A
170666.29
D
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $142.09 to $142.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $143.13 to $143.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $144.15 to $144.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
/s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person
2019-03-07